Methotrexate for Juvenile Idiopathic Arthritis

Kento Sonoda, MD, AAHIVS, FAAFP, FASAM

Kelly Dougherty, MD

American Family Physician. 2025;111(5):402-403.

Author disclosure: No relevant financial relationships.

KENTO SONODA, MD, AAHIVS, FAAFP, FASAM, Saint Louis University, St. Louis, Missouri

KELLY DOUGHERTY, MD, Mercy St. Louis Family Medicine Residency, St. Louis

Address correspondence to Kento Sonoda, MD, AAHIVS, FAAFP, FASAM, at kento.sonoda@health.slu.edu.

Author disclosure: No relevant financial relationships.

1.Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996–2009. J Rheumatol. 2013;40(7):1218-1225.
2.Tharwat S, Nassar MK, Salem KM, et al. Extraarticular manifestations of juvenile idiopathic arthritis and their impact on health-related quality of life. Clin Rheumatol. 2024;43(7):2295-2305.
3.Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2022;74(4):521-537.
4.Tan J, Renton WD, Whittle SL, et al. Methotrexate for juvenile idiopathic arthritis. Cochrane Database Syst Rev. 2024(2):CD003129.
5.Ferrara G, Mastrangelo G, Barone P, et al.; Rheumatology Italian Study Group. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46.